Most people read a lab report like a report card. Blood pressure: borderline. Cholesterol: normal. Fasting glucose: slightly high. Weight: up a few pounds. Each line gets a mental pass or fail, and the conversation moves on.
That approach misses how the body actually works. Cardiometabolic health is a single interconnected risk system, not a checklist. Each marker influences and amplifies the others.
The stakes are significant. A JACC-published analysis of NHANES data found that only 6.8% of American adults have optimal cardiometabolic health, and population health worsened between 1999–2000 and 2017–2018.
This article explains how these markers interact, how hormonal shifts with age (menopause in women, declining testosterone in men) change the system’s trajectory even when individual numbers look fine, and why ongoing monitoring is a more appropriate response than a one-time test.
What Cardiometabolic Health Actually Means
The American Diabetes Association uses the term “cardiometabolic health” to describe a person’s level of risk for type 2 diabetes and cardiovascular disease. Rather than a single diagnosis, it represents a cluster of modifiable and nonmodifiable factors that predict either condition.
That distinction matters. Cardiovascular disease is the downstream event, such as a heart attack or stroke. Cardiometabolic health is the upstream risk architecture that makes those events more or less likely.
The numbers show how common the problem is:
- NHANES 2007–2014 data put cardiometabolic syndrome at 35.3% of men and 33.3% of women, rising with age and highest among Black women (40%).
- Roughly 31% of all deaths worldwide are associated with cardiometabolic disease.
The Interconnected Risk System: How One Marker Moves the Others
Cardiometabolic risk rarely stems from a single factor. Abdominal obesity, elevated blood sugar, dyslipidemia, and high blood pressure act together to damage blood vessels and organs.
Consider a common sequence. Visceral fat, the fat stored around the organs, drives insulin resistance. Insulin resistance raises triglycerides and lowers HDL cholesterol. That lipid pattern, combined with metabolic stress, strains blood pressure regulation. Each change reinforces the next. It is a feedback loop, not a line item.
Metabolic Syndrome: The Minimum Risk Cluster
The core criteria for metabolic syndrome include:
- Abdominal obesity: waist of 40 inches or more in men, 35 inches or more in women
- High fasting triglycerides
- Low HDL cholesterol
- Elevated blood pressure
Having two or more of these factors doubles heart attack and stroke risk and raises diabetes risk five-fold over five to ten years. Importantly, a person can have each number sitting just below its diagnostic line while the combination still meaningfully elevates risk.
The Bigger Picture: Cardiovascular-Kidney-Metabolic (CKM) Syndrome
In 2023, the American Heart Association’s Presidential Advisory formally defined CKM syndrome as a staged condition (Stage 0 to 4) linking obesity, diabetes, chronic kidney disease, and cardiovascular disease. Screening frequency and intensity are tied to stage, which frames this as a progression to track rather than a test to pass.
CKM syndrome affects more than 30% of adults over 40. In one cohort, only 10.5% of adults over 45 were in good CKM health (Stage 0), and 27.2% deteriorated within four years. People with cardiometabolic syndrome also face twice the likelihood of developing and dying from cardiovascular disease, and more than seven times the diabetes risk, compared with those who have no risk factors.
Why “Borderline Normal” Can Still Mean Real Risk
A single value just inside the reference range does not mean the overall system is low-risk. Reference ranges evaluate one marker at a time; the body does not.
This is why clinicians increasingly look at clustering and trajectory. The direction of change across several markers over time often says more than any one result.
There is also a shift toward body composition over BMI. Fat distribution and visceral adiposity predict cardiometabolic risk more reliably than a simple weight-to-height ratio.
The Hormonal Shift That Changes the Whole Trajectory
Aging-related hormonal change does not simply add a fifth risk factor. It alters how the existing four interact and can accelerate the whole system.
Menopause and the Female Cardiometabolic Shift
During perimenopause and menopause, fluctuating and declining estrogen affects cholesterol, insulin resistance, blood pressure, and weight regulation at the same time. A 2026 study in the Journal of the American Heart Association found that perimenopausal women were twice as likely to have a low cardiovascular health score as women with regular cycles.
The mechanism connects directly to the waist-circumference criterion. Estrogen decline disrupts lipid balance and shifts fat storage toward the abdomen, increasing visceral fat and metabolic syndrome risk.
Newer 2026 research from Virginia Tech suggests that menopause-related cardiovascular risk also stems from epigenetic changes in gene regulation, not estrogen decline alone. That points to a more individualized risk picture than any single hormone level can explain. A woman in perimenopause may have every number technically in range while her trajectory has already shifted.
Declining Testosterone and the Male Cardiometabolic Shift
In men, low testosterone promotes visceral fat and insulin resistance, creating conditions favorable to atherosclerosis. Testosterone deficiency affects over 52% of men with abdominal obesity and roughly 50% of men with insulin resistance or type 2 diabetes. Men with hypogonadal levels have been shown to be twice as insulin resistant as men with normal levels, with mitochondrial dysfunction proposed as one contributing mechanism.
The relationship runs both ways. Poor metabolic health lowers testosterone, and low testosterone worsens metabolic markers. Addressing cardiometabolic dysfunction (cholesterol, blood sugar, inflammation) may support testosterone status, not just the reverse. That is a strong reason not to treat testosterone as a standalone issue.
Why Standard Labs Often Miss the Full Risk Picture
A basic lipid panel and fasting glucose can look unremarkable while deeper markers already signal risk. Major diagnostic labs now offer advanced panels that combine HbA1c, insulin resistance scoring, ApoB, Lipoprotein(a), and inflammatory markers to catch residual risk that standard panels miss.
Body composition belongs in that assessment as well. Visceral fat distribution is a more precise predictor than weight or BMI alone.
From Snapshot to System: Why Ongoing Monitoring Is the Right Response
Because cardiometabolic risk is a moving system, and hormonal change unfolds over years, a single panel is only a snapshot of a trajectory already in motion.
Staged, periodic reassessment, echoing the AHA’s CKM approach, is more useful than testing only when something feels wrong. Tracking markers over time reveals direction and rate of change. Monitoring hormonal and cardiometabolic markers together also captures the feedback loop between them, producing a more complete and actionable picture than either alone.
What This Looks Like in Practice
A clinically led, in-person approach typically involves:
- Periodic labs
- Body composition tracking
- Blood pressure and lipid trend review
- Hormone-level reassessment over time
The key is interpreting these together. Purchasing a panel produces data; physician-guided interpretation explains what the combination means and what to adjust.
Red Mountain, drawing on more than 30 years of patient outcomes and a network of brick-and-mortar clinics, approaches this as an ongoing relationship across life stages: perimenopause, menopause, andropause, and beyond. Metabolic foundation work, hormone optimization, and long-term maintenance are treated as connected stages of the same process rather than separate purchases.
Conclusion: Treat the System, Not the Snapshot
Blood pressure, cholesterol, glucose, weight, and hormone levels are not independent line items. They are interacting parts of one evolving risk system. “Borderline normal” numbers can still represent meaningful risk once hormonal aging is factored in, and that risk compounds quietly over years when no one is watching the trend. Ongoing lab work and monitoring, rather than a single test or a single fix, is the measured, adult response.
Next Step: Understanding Where Things Stand
Understanding how individual markers interact, and whether hormonal shifts are already influencing the trajectory, is best done through a clinical conversation rather than self-interpreting isolated numbers. Labs, body composition, and hormone status considered together form the integrated picture that gets discussed in a consult.
For those who recognize this pattern, a consult is usually the next step toward a clear, personalized read on where things stand.
